our expertise.

IntelliSyn delivers excellence, innovation, and efficiency at each stage of drug discovery. More than 75% of our scientists have Ph.D. degrees and post-doctoral work at leading universities in the US, Canada, or Europe. Our lead scientists have 15-25 years of experience within major pharma, including AstraZeneca, Boehringer Ingelheim, and Merck.

IntelliSyn understands the importance of project timelines, data management, predictive capabilities, and multi-parameter optimization. We have experienced firsthand the risks and opportunities of CRO collaborations within North America and Asia. We recognize that independent problem solving, high data quality, accountability, and transparent communication are critical for consistent project advancement.



We have prior or ongoing projects in these areas:

  • Psychiatry
  • Neurology
  • Pain
  • Oncology
  • Pulmonary disease
  • Endocrinology and Metabolism


We have prior or ongoing projects in these areas:

  • GPCRs
  • Ion channels
  • Transporters
  • Enzymes
  • Epigenetic readers
  • Epigenetic writers
  • Protein-protein interactions


Our scientists were trained at some of the most demanding academic labs in North America, and we vigilantly maintain awareness of innovations and developing methodologies so we can develop the best methods for our clients’ projects.

Our seasoned research scientists ensure that our synthetic strategies are aligned to deliver not just potent compounds, but compounds that are designed to minimize risks and attrition during clinical development.

We have particular expertise in total synthesis, asymmetric synthesis, organometallic chemistry, and multi-dimensional NMR. We use a mixture of both trusted and innovative technologies to maximize synthetic productivity and compound quality.